STOCKHOLM, June 14, 2018 /PRNewswire/ -- Nasdaq Stockholm's listing committee has approved
that Nuevolution AB (publ)'s ("Nuevolution") shares are admitted to
trading on Nasdaq Stockholm's main market. The approval is subject
to customary conditions, including the approval and registration of
a prospectus by the Swedish Financial Supervisory Authority. Last
day of trading on Nasdaq First North Premier is expected to be
Thursday 21 June and first day of trading on Nasdaq Stockholm is
expected to be Monday 25 June
2018.
The shares will be traded in the Small Cap segment under the
same ticker (NUE) and with the same ISIN code (SE0007730650). No
new shares will be issued in connection with the listing.
Shareholders of Nuevolution do not need to take any action in
connection with the delisting from Nasdaq First North Premier or
the listing on Nasdaq Stockholm.
"Since our IPO on First North Premier in December 2015, we have realized several
milestones from existing partnerships, we have entered two new and
major partnership agreements with Amgen and Almirall, we have built
the world largest screening collection of synthetic molecules for
drug discovery of tablet-based medicines, we have matured our
pipeline to be closer to clinical development than ever, and we
have broadened the shareholder base. With this step of listing on
the main market, we hope to stimulate further interest from
institutional as well as international investors for investing in
Nuevolution AB (publ). All of this would not have been possible
without the strong and loyal support that we see from our
investors. Thank you!", said Alex Haahr
Gouliaev, Chief Executive Officer.
Prospectus
Nuevolution has prepared a prospectus in connection with the
admission to trading of the company's shares on Nasdaq Stockholm.
The prospectus is expected to be approved by the Swedish Financial
Supervisory Authority and published on the company's website on or
about 20 June 2018.
Advisors
In connection with the listing on Nasdaq Stockholm, Carnegie
Investment Bank has acted financial advisor, and Advokatfirman
Vinge has acted legal advisor.
For further information, please contact:
Alex Haahr Gouliaev, CEO
Phone:
+45-7020-0987
E-mail: ahg@nuevolution.com
Henrik D. Simonsen,
CFO
Phone:
+45-3913-0947
E-mail:
hs@nuevolution.com
This is information that Nuevolution AB (publ) is obliged to
make public pursuant to the EU Market Abuse Regulation. The
information was sent for publication, through the agency of the
contact persons set out above, on 16.30 CET on 14 June
2018.
About Nuevolution AB (publ)
Nuevolution AB (publ) is a leading small molecule drug discovery
biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its
discovery platform and programs with pharmaceutical and
biotechnology companies to seek future benefit of patients in need
of novel medical treatment option. Nuevolution's internal programs
are focused on therapeutically important targets within
inflammation, oncology and immuno-oncology.
Nuevolution AB (publ) is listed at Nasdaq First North in
Stockholm, Sweden (ticker: NUE).
Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More
information about Nuevolution can be found on:
www.nuevolution.com.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/nuevolution/r/nuevolution-approved-for-listing-on-nasdaq-stockholm,c2548869
The following files are available for download:
http://mb.cision.com/Main/13526/2548869/860533.pdf
|
PDF
|
View original
content:http://www.prnewswire.com/news-releases/nuevolution-approved-for-listing-on-nasdaq-stockholm-300666513.html
SOURCE Nuevolution